

CircLRBA is highly expressed in breast cancer (BC) and associated with poor overall survival. Zeb1 mediated circLRBA facilitates BC cell proliferation, invasion, docetaxel (DTX) resistance and inhibits the infiltration of CD8+ T cell. CircLRBA could combine with SPOP to suppress the Twist1 ubiquitination degradation and enhances PD‐L1 transcription, thus promoting EMT, immune evasion, chemoresistance and BC progression. This study highlights circLRBA might serve as a promising biomarker and potential therapeutic target for BC. Abstract Breast cancer (BC) is a malignant tumor with the highest incidence in women. Metastasis is the leading cause of BC‐related death. Circular RNAs (circRNAs) play important roles in cancer progression and metastasis, therefore exploring its specific mechanism in BC metastasis has high value. However, the biological roles and potential mechanism of circRNAs in BC remain unclear. Here, a highly expressed circRNA circLRBA in BC tissues is identified using high‐throughput sequencing, which is associated with pathological stage and poor overall survival. Functional assays show that circLRBA facilitates BC cell proliferation, invasion, migration, docetaxel (DTX) resistance, and inhibits the infiltration of CD8+ T cell in vitro and in vivo. Whereas circLRBA knockdown reveals opposite roles. Mechanistically, transcription factor Zeb1 promotes the generation of circLRBA. Importantly, circLRBA could competitively combine with E3 ubiquitin ligase SPOP to suppress the Twist1 ubiquitination degradation and enhances PD‐L1 transcriptional activity, thus promoting EMT, immune evasion, chemoresistance and BC progression. This study highlights the oncogenic role of circLRBA in BC progression through its binding with SPOP to increases Twist1 stability, suggesting that circLRBA might serve as a promising biomarker and potential therapeutic target for BC. CircLRBA is highly expressed in breast cancer (BC) and associated with poor overall survival. Zeb1 mediated circLRBA facilitates BC cell proliferation, invasion, docetaxel (DTX) resistance and inhibits the infiltration of CD8+ T cell. CircLRBA could combine with SPOP to suppress the Twist1 ubiquitination degradation and enhances PD-L1 transcription, thus promoting EMT, immune evasion, chemoresistance and BC progression. This study highlights circLRBA might serve as a promising biomarker and potential therapeutic target for BC. Abstract Breast cancer (BC) is a malignant tumor with the highest incidence in women. Metastasis is the leading cause of BC-related death. Circular RNAs (circRNAs) play important roles in cancer progression and metastasis, therefore exploring its specific mechanism in BC metastasis has high value. However, the biological roles and potential mechanism of circRNAs in BC remain unclear. Here, a highly expressed circRNA circLRBA in BC tissues is identified using high-throughput sequencing, which is associated with pathological stage and poor overall survival. Functional assays show that circLRBA facilitates BC cell proliferation, invasion, migration, docetaxel (DTX) resistance, and inhibits the infiltration of CD8+ T cell in vitro and in vivo. Whereas circLRBA knockdown reveals opposite roles. Mechanistically, transcription factor Zeb1 promotes the generation of circLRBA. Importantly, circLRBA could competitively combine with E3 ubiquitin ligase SPOP to suppress the Twist1 ubiquitination degradation and enhances PD-L1 transcriptional activity, thus promoting EMT, immune evasion, chemoresistance and BC progression. This study highlights the oncogenic role of circLRBA in BC progression through its binding with SPOP to increases Twist1 stability, suggesting that circLRBA might serve as a promising biomarker and potential therapeutic target for BC. Advanced Science, Volume 12, Issue 48, December 29, 2025.
Medical Journal
|15th Jan, 2026
|Nature Medicine's Advance Online Publication (AOP) table of contents.
Medical Journal
|15th Jan, 2026
|Wiley
Medical Journal
|15th Jan, 2026
|Wiley
Medical Journal
|15th Jan, 2026
|Wiley
Medical Journal
|15th Jan, 2026
|Wiley
Medical Journal
|15th Jan, 2026
|Wiley
Medical Journal
|15th Jan, 2026
|Wiley